Transient bevacizumab (avastin)-induced alterations in rat eyes

Ophthalmic Research

Volumn 41, Issue 1, 2008, Pages 28-35

  Sancho Tello, María ^a,c   Johnsen Soriano, Siv ^a   Muriach, María ^a   Bosch Morell, Francisco ^a   Díaz Llopis, Manuel ^b   Palacios Pozo, Elena ^a   Navea, Amparo ^a   Romero, Francisco Javier ^a,d  

^a UNIVERSIDAD CEU CARDENAL HERRERA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

^d Fundación Oftalmológic del Mediterráneo   (Spain)

Author keywords

Bevacizumab, intravitreal injection; Electroretinogram; Inflammation; Oxidative stress, rat

Indexed keywords

BEVACIZUMAB; GLUTATHIONE PEROXIDASE; MALONALDEHYDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS HUMOR; ARTICLE; CELL INFILTRATION; CHEMICAL ANALYSIS; CONTROLLED STUDY; DRUG MEGADOSE; ELECTRORETINOGRAM; EYE INFLAMMATION; HISTOPATHOLOGY; MALE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; RAT; WISTAR RAT;

ANALYSIS OF VARIANCE; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; CELL COUNT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ELECTRORETINOGRAPHY; EYE; GLUTATHIONE PEROXIDASE; MALE; MALONDIALDEHYDE; OCULAR PHYSIOLOGICAL PHENOMENA; OXIDATIVE STRESS; RATS; RATS, WISTAR; REACTION TIME; SPECTROPHOTOMETRY; TIME FACTORS;

EID: 53549083233     PISSN: 00303747     EISSN: None     Source Type: Journal    
DOI: 10.1159/000162263     Document Type: Article

References (42)

1. Ferrara N: VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002;2:795-803.
2. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-1309.
3. Ferrara N: Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611.
4. Dvorak HF: Vascular permeability factor/ vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368-4380.
5. D'Amore PA: Mechanisms of retinal and choroidal neovascularization. Invest Ophthalmol Vis Sci 1994;35:3974-3979.
6. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, Smith LE: Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995;92:10457-10461.
7. Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK, Yeo KT: Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994;118:445-450.
8. Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP: Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 1998;39:18-22.
9. Kvanta A, Algvere PV, Berglin L, Seregard S: Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996;37:1929-1934.
10. Wells JA, Murthy R, Chibber R, Nunn A, Molinatti PA, Kohner EM, Gregor ZJ: Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation. Br J Ophthalmol 1996;80:363-366.
11. Qaum T, Xu Q, Joussen AM, Clemens MW, Qin W, Miyamoto K, Hassessian H, Wiegand SJ, Rudge J, Yancopoulos GD, Adamis AP: VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 2001;42:2408-2413.
12. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-4599.
13. Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW Jr, Gonzalez S, Feuer WJ, Lin RC, Lalwani GA, Nguyen JK, Kumar G: Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511.
14. Shahar J, Avery RL, Heilweil G, Barak A, Zemel E, Lewis GP, Johnson PT, Fisher SK, Perlman I, Loewenstein A: Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006;26:262-269.
15. Avery RL: Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26:352-354.
16. Bakri SJ, Cameron JD, McCannel CA, Pulido JS, Marler RJ: Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Am J Ophthalmol 2006;142:162-164.
17. Feiner L, Barr EE, Shui YB, Holekamp NM, Brantley MA Jr: Safety of intravitreal injection of bevacizumab in rabbit eyes. Retina 2006;26:882-888.
18. Manzano RP, Peyman GA, Khan P, Kivilcim M: Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006;26:257-261.
19. Maturi RK, Bleau LA, Wilson DL: Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26:270-274.
20. Inan UU, Avci B, Kusbeci T, Kaderli B, Avci R, Temel SG: Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Vis Sci 2007;48:1773-1781.
21. Peters S, Heiduschka P, Julien S, Ziemssen F, Fietz H, Bartz-Schmidt KU, Schraermeyer U: Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 2007;143:995-1002.
22. Miranda M, Muriach M, Johnsen S, Bosch-Morell F, Araiz J, Roma J, Romero FJ: Oxidative stress in a model for experimental diabetic retinopathy: treatment with antioxidants. Arch Soc Esp Oftalmol 2004;79:289-294.
23. Muriach M, Bosch-Morell F, Alexander G, Blomhoff R, Barcia J, Arnal E, Almansa I, Romero FJ, Miranda M: Lutein effect on retina and hippocampus of diabetic mice. Free Radic Biol Med 2006;41:979-984.
24. Doly M, Droy-Lefaix MT: Lipid peroxidation in the pathology of the retina; in Packer L, Prilipko L, Christen Y (eds): Free Radical in Brain Aging: Neurological and Mental Disorders. Berlin, Springer, 1992, pp 133-142.
25. Doly M, Droy-Lefaix MT, Braquet P: Oxidative stress in diabetic retina. EXS 1992;62:299-307.
26. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
27. Peterson GL: A simplification of the protein assay method of Lowry et al which is more generally applicable. Anal Biochem 1977;83:346-356.
28. Romero MJ, Bosch-Morell F, Romero B, Rodrigo JM, Serra MA, Romero FJ: Serum malondialdehyde: possible use for the clinical management of chronic hepatitis C patients. Free Radic Biol Med 1998;25:993-997.
29. Richard MJ, Guiraud P, Meo J, Favier A: High-performance liquid chromatographic separation of malondialdehyde-thiobarbituric acid adduct in biological materials (plasma and human cells) using a commercially available reagent. J Chromatogr 1992;577:9-18.
30. Paglia DE, Valentine WN: Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967;70:158-169.
31. Moorthy RS, Valluri S, Jampol LM: Drug-induced uveitis. Surv Ophthalmol 1998;42:557-570.
32. Fraunfelder FW, Fraunfelder FT: Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side Effects. Ophthalmology 2004;111:1275-1279.
33. Cano Parra J, Diaz-Llopis M: Drug induced uveitis (in Spanish). Arch Soc Esp Oftalmol 2005;80:137-149.
34. Calonge M: Medication-induced uveitis; in Foster C, Vitale AT (eds): Diagnosis and Treatment of Uveitis. Philadelphia, Saunders, 2002, pp 859-867.
35. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ: Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114:855-859.
36. Pieramici DJ, Avery RL, Castellarin AA, Nasir MA, Rabena M: Case of anterior uveitis after intravitreal injection of bevacizumab. Retina 2006;26:841-842.
37. Kiss C, Michels S, Prager F, Weigert G, Geitzenauer W, Schmidt-Erfurth U: Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab. Retina 2006;26:877-881.
38. Jonas JB, Spandau UH, Schlichtenbrede F: Intravitreal bevacizumab for filtering surgery. Ophthalmic Res 2007;39:121-122.
39. Berkowitz BA, Lukaszew RA, Mullins CM, Penn JS: Impaired hyaloidal circulation function and uncoordinated ocular growth patterns in experimental retinopathy of prematurity. Invest Ophthalmol Vis Sci 1998;39:391-396.
40. Luke M, Warga M, Ziemssen F, Gelisken F, Grisanti S, Schneider T, Luke C, Partsch M, Bartz-Schmidt KU, Szurman P: Effects of bevacizumab on retinal function in isolated vertebrate retina. Br J Ophthalmol 2006;90:1178-1182.
41. Bosch-Morell F, Roma J, Puertas FJ, Marin N, Diaz-Llopis M, Romero FJ: Efficacy of the antioxidant ebselen in experimental uveitis. Free Radic Biol Med 1999;27:388-391.
42. Bosch-Morell F, Roma J, Marin N, Romero B, Rodriguez-Galietero A, Johnsen-Soriano S, Diaz-Llopis M, Romero FJ: Role of oxygen and nitrogen species in experimental uveitis: anti-inflammatory activity of the synthetic antioxidant ebselen. Free Radic Biol Med 2002;33:669-675.